Literature DB >> 8580613

The detection and management of dyslipidaemia in children and adolescents.

L Ose1, S Tonstad.   

Abstract

Previous algorithms regarding treatment of children with dyslipidaemia do not distinguish sufficiently between children at very high risk for cardiovascular disease and those with less exceptional risk. We propose that physicians assess risk, taking into consideration the nature of the genetic disorder, the severity of hypercholesterolaemia and the family history. Screening should be limited to children with suspected familial hypercholesterolaemia. Guidelines for individualized dietary and drug therapy are suggested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580613

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  5 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Lipid lowering in the young.

Authors:  G R Thompson
Journal:  Heart       Date:  1996-07       Impact factor: 5.994

Review 3.  A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits.

Authors:  S Tonstad
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

4.  Hereditary dyslipidemias and combined risk factors in children with a family history of premature coronary artery disease.

Authors:  T Sveger; C E Flodmark; K Nordborg; P Nilsson-Ehle; N Borgfors
Journal:  Arch Dis Child       Date:  2000-04       Impact factor: 3.791

Review 5.  Choices for treatment of hyperlipidaemia.

Authors:  S Tonstad
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.